GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » Cash Conversion Cycle

Clal Biotechnology Industries (XTAE:CBI) Cash Conversion Cycle : 0.00 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Clal Biotechnology Industries's Days Sales Outstanding for the three months ended in Dec. 2023 was 0.
Clal Biotechnology Industries's Days Inventory for the three months ended in Dec. 2023 was 0.
Clal Biotechnology Industries's Days Payable for the three months ended in Dec. 2023 was 0.
Therefore, Clal Biotechnology Industries's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 0.00.


Clal Biotechnology Industries Cash Conversion Cycle Historical Data

The historical data trend for Clal Biotechnology Industries's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries Cash Conversion Cycle Chart

Clal Biotechnology Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.07 20,452.40 11,753.33 5,459.22 -

Clal Biotechnology Industries Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 5,022.57 - - -

Competitive Comparison of Clal Biotechnology Industries's Cash Conversion Cycle

For the Biotechnology subindustry, Clal Biotechnology Industries's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clal Biotechnology Industries's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clal Biotechnology Industries's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Clal Biotechnology Industries's Cash Conversion Cycle falls into.



Clal Biotechnology Industries Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Clal Biotechnology Industries's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+0-0
=0.00

Clal Biotechnology Industries's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clal Biotechnology Industries  (XTAE:CBI) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Clal Biotechnology Industries Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries (XTAE:CBI) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries (XTAE:CBI) Headlines

From GuruFocus

Van Den Berg Reduces Position in 5-Star Company

By Kyle Ferguson Kyle Ferguson 01-25-2016

CB&I Announces DPC Technology Award in China

By PRNewswire PRNewswire 04-03-2018

Does the Increase in Volatility Signal a Dangerous Market Environment?

By Chuck Carnevale Chuck Carnevale 11-11-2016

Seeking Value in the Construction Industry

By Mark Yu Mark Yu 07-03-2017

Richard Snow Increases His Stake in Chicago Bridge and Iron

By Ashish Sharma Lalitsharma 09-14-2015

Should We Devote Attention to Market Factors?

By Grahamites Grahamites 08-25-2015